CSIMarket Company Name, Ticker, Competitors, else..
 
Journey Medical Corp  (NASDAQ: DERM)
 
Price: $7.4100 $-0.06 -0.803%
Day's High: $7.489999771118164 Week Perf: -1.59 %
Day's Low: $ 7.25 30 Day Perf: 16.33 %
Volume (M): 65,515 52 Wk High: $ 9.56
Volume (M$): $ 0 52 Wk Avg: $7.07
Open: $7.49 52 Wk Low: $4.31



 Market Capitalization (Millions $) 202
 Shares Outstanding (Millions) 27
 Employees 58
 Revenues (TTM) (Millions $) 65
 Net Income (TTM) (Millions $) -10
 Cash Flow (TTM) (Millions $) 6
 Capital Exp. (TTM) (Millions $) 0

Business Description


Journey Medical Corporation is a company focused on developing and marketing innovative dermatological products. They specialize in providing solutions for a wide range of skin conditions, including acne, psoriasis, eczema, and more. Journey Medical Corporation works closely with dermatologists, healthcare providers, and patients to create effective treatment options that improve the lives of those suffering from skin conditions. The company is committed to advancing dermatology through research, innovation, and education, with the ultimate goal of empowering patients and improving their skin health.


   Company Address: 9237 E Via de Ventura Blvd. Scottsdale 85258 AZ
   Company Phone Number: 434-6670   Stock Exchange / Ticker: NASDAQ DERM


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -3.06%    
BMY   -0.7%    
JNJ   -2.63%    
LLY   -7.23%    
MRK   -1.92%    
PFE        1.75% 
• View Complete Report
   



Product Service News

Transformative Milestones in Dermatology FDA Approves Journey Medical’s Emrosi for Rosacea Management,

Published Mon, Nov 4 2024 12:01 PM UTC

Revolutionizing Rosacea Treatment: Journey Medical Corporation s Emrosi Receives FDA ApprovalIn a significant advancement for dermatological therapeutics, Journey Medical Corporation has announced that the U.S. Food and Drug Administration (FDA) has approved Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of rosacea. This newly approved...
Clinical Study

Augmenting Dermatology: Journey Medical Corporation's DFD-29 Shows Promise in Impacting Healthy Adults' Microbial Flora

Published Mon, Mar 11 2024 12:31 PM UTC

Journey Medical Corporation recently announced the presentation of data from a Phase 1 clinical trial assessing the impact of their flagship product, DFD-29, on the microbial flora of healthy adults. This significant milestone was shared at the 2024 American Academy of Dermatology (AAD) Annual Meeting. The company successfully achieved all three primary s of the trial, with ...
Product Service News

DFD-29: The Future of Rosacea Treatment Glimmers Bright as Journey Medical Corporation Seeks FDA approval.

Published Fri, Jan 5 2024 1:30 PM UTC

Journey Medical Corporation has recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for DFD-29, potentially heralding a breakthrough triumph in the treatment of Rosacea. If approved, DFD-29 has the potential to dominate the market as the best-in-class and the only oral medication that addresses both inflammatory lesions and erythema...
Financing Agreement

Journey Medical's $20 Million Credit Facility Expands Horizons, Paves the Way for DFD-29's Revolutionary Dermatology Breakthrough

Published Tue, Jan 2 2024 9:06 PM UTC

Journey Medical Corporation Secures Credit Facility from SWK Holdings, Opening Doors for Future Growth and Innovation
In an exciting development for Journey Medical Corporation, the company has successfully secured a credit facility with SWK Holdings for up to $20 million. This newfound financial support not only strengthens Journey s position in the market but also prop...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 3.13
Price to Sales (Expected) -
Price to Book 6.56
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.72
Working Capital Ratio 1.72
Leverage Ratio (MRQ) 1.97
Total Debt to Equity 0.82
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.38 $
Revenues (TTM) 2.37 $
Cash Flow (TTM) 0.23 $
Cash 1 $
Book Value 1.13 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 1,115,172
Net Income per Employee (TTM) -165,310
Receivable Turnover Ratio (TTM) 2.93
Inventory Turnover Ratio (TTM) 2.05
Asset Turnover Ratio (TTM) 0.74

Profitability Ratios Current
Gross Margin (MRQ) 61.04 %
Operating Margin (MRQ) -9.35 %
Net Margin (MRQ) -13.97 %
Net Cash Flow Margin (MRQ) 19.6 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Journey Medical's Segments
Emrosi    39.17 % of total Revenue
Qbrexza    31.5 % of total Revenue
Accutane    20.76 % of total Revenue
Foam franchise products Amzeeq Zilxi    6.58 % of total Revenue
Other legacy    1.74 % of total Revenue
Dermatological segment    100 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.